<?xml version="1.0" encoding="UTF-8"?>
<p>Human dengue immune sera used in this study were obtained from a previously described Dengue Traveler collection at University of North Carolina, and were all primary DENV2 natural infections [
 <xref rid="ppat.1006934.ref024" ref-type="bibr">24</xref>,
 <xref rid="ppat.1006934.ref025" ref-type="bibr">25</xref>,
 <xref rid="ppat.1006934.ref030" ref-type="bibr">30</xref>]. Vaccine sera were obtained from individuals who received a live-attenuated monovalent DENV2 vaccine as developed by the US National Institutes of Health (NIH) and were provided by Anna Durbin and Stephen Whitehead. All human sera samples were obtained under Institutional Review Board approval and were anonymized.
</p>
